Book Details
Orange Code:30030
Paperback:259 pages
Publications:
Categories:
Sections:
1. Some Aspects of Computational Chemistry2. Computer-Aided Drug Design in Industrial ResearchA Management Perspective3. Reflections on Collaborations of a Computational Chemist with Medicinal Chemists and Other Scientists4. Structure-Based Ligand Design K. Gubemator, C. Brager, D. Bur, D. M. Doran5. Chances and Risks of Modeling in Industry6. The Advantages of Using Rational Drug Design in Modem Drug Discovery: How to Integrate Computer-Aided Drug Design and Modem Biotechnology7. Optimization of Peptide Leads and Molecular Modeling8. Quantitative Structure-Activity Relationships and Crystallography in Industrial Drug Design9. The Role of Structure-Based Ligand Design in Industrial Pharmaceutical Research10. Drug Design Methods in Real-Life Situations: Recent Examples and Future Opportunities11. Theoretical Chemistry as Part of the Interdisciplinary Approach to Rational Drug Design12. Computer-Aided Drug Design in Industry: A Summary of Perspectives
Description:
The Ernst Schering Research Foundation sponsored its 15th workshop in Berlin on October 19-21, 1994. Leading scientists from Europe and North America were invited to discuss computer-aided drug design in industrial research. Computer-aided drug design is a very exciting field and an intellec tual challenge, like playing chess. But these reasons are no longer suf ficient to justify using this method in industry, if they ever were. Fig. 1. The participants of the workshop VI Preface Therefore, when we, together with Prof. Hoyer, started to think about this workshop, our intentions quickly became clear. We were not so much interested in the very latest developments of methods or in computer-aided drug design itself - enough conferences have dealt with these topics. However, we were very interested in the usefulness and limitations of computer-aided drug design in the indu strial research process. A lot has changed in the pharmaceutical industry recently. These changes are gaining momentum, so it is the right time to think about the role of computer-aided drug design in this changing environment.
|